◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocks0-9 › 0108

SR Medical Technology Company Limited (0108) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Real Estate · Real Estate Services · DATA UPDATED 2026-08-10

SR Medical Technology Company Limited (0108) operates in the Real Estate Services industry and is headquartered in Central, Hong Kong with about 438 employees. Its market capitalization is roughly HKD 5 billion. In the fiscal year ended 2025-12-31, 0108 reported HKD 328M in revenue and (HKD 110M) in net income.

SR Medical Technology Company Limited, together with its subsidiaries, engages in the property development and investment business in the United Kingdom, the United States, and the People's Republic of China. It operates in two segments, Property Development and Investment, and Property Management.

Interactive charts & full statements →

0108 Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-312021-12-31
Total RevenueHKD 328MHKD 310MHKD 353MHKD 352M
Gross ProfitHKD 209MHKD 199MHKD 244MHKD 230M
Operating Income (EBIT)HKD 63MHKD 71MHKD 137MHKD 136M
Net Income(HKD 110M)(HKD 918M)(HKD 129M)(HKD 320M)

HKD; HKDM / HKDB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

0108 Free Cash Flow History

0108 Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total AssetsHKD 5.7BHKD 5.4BHKD 6.4BHKD 6.2B
Total LiabilitiesHKD 3.6BHKD 3.3BHKD 3.3BHKD 3.0B

HKD; HKDM / HKDB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 0108 viewer.

Other Companies in Real Estate Services

← 0107All “0-9” companies0110 →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.